Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Health Canada has approved Novo Nordisk’s semaglutide injection, Wegovy, to reduce the risk of non-fatal myocardial ...

Health Canada has approved Novo Nordisk's weight-loss drug Wegovy to reduce the risk of non-fatal heart attack, the drug maker says. Novo Nordisk said Wednesday that Wegovy is the first Health ...

Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s labor market in the ...

Patients in China will be able to purchase the blockbuster weight-loss drug Wegovy for 1,400 yuan, or about $193, just a ...

According to Reuters and CNN, Novo Nordisk announced Monday that it has launched its popular obesity drug Wegovy in China, ...

Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...

Four oral glucagon-like peptide-1 receptor (GLP1R) drugs, currently under Phase III trials, are in the race for approval, ...

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

Novo Nordisk is a global leader in healthcare, renowned for its groundbreaking innovations in diabetes and obesity treatment, notably through products like Ozempic and Wegovy. Under the leadership ...